Enzastaurin HCL
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Carcinoma
Conditions
Non-Small-Cell Lung Carcinoma
Trial Timeline
Mar 1, 2005 → Feb 1, 2007
NCT ID
NCT00105092About Enzastaurin HCL
Enzastaurin HCL is a phase 2 stage product being developed by Eli Lilly for Non-Small-Cell Lung Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00105092. Target conditions include Non-Small-Cell Lung Carcinoma.
What happened to similar drugs?
7 of 20 similar drugs in Non-Small-Cell Lung Carcinoma were approved
Approved (7) Terminated (6) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00192114 | Phase 2 | Completed |
| NCT00105092 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Small-Cell Lung Carcinoma